Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (141-150 of 418) with videos related to

Pageof 42
Sort By:
The Journal of Investigative Dermatology|March 20, 2015
MITF Modulates Therapeutic Resistance through EGFR SignalingZhenyu Ji, Yiyin Erin Chen, Raj Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2011
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancerKeith T Flaherty, Patricia M Lorusso, Angela Demichele, et al.
Molecular Cancer Therapeutics|June 21, 2023
Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant MelanomaMcKenna Q Glasheen, Signe Caksa, Amelia G Young, et al.
Pigment Cell & Melanoma Research|February 1, 2017
MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathwayLisa Koetz-Ploch, Douglas Hanniford, Igor Dolgalev, et al.
Cancer Research|July 18, 2008
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpressionKeiran S M Smalley, Rooha Contractor, Thiennga K Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
Phase I trial of combretastatin a-4 phosphate with carboplatinJoshua H Bilenker, Keith T Flaherty, Mark Rosen, et al.
Cancer Discovery|December 28, 2014
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanomaBenchun Miao, Zhenyu Ji, Li Tan, et al.
Pigment Cell & Melanoma Research|November 29, 2011
Meeting report from the 2011 International Melanoma Congress, Tampa, FloridaKeiran S M Smalley, Andrew E Aplin, Keith T Flaherty, et al.
Oncoimmunology|November 20, 2013
BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytesZachary A Cooper, Dennie T Frederick, Vikram R Juneja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2008
Phase II trial of sorafenib in advanced thyroid cancerVandana Gupta-Abramson, Andrea B Troxel, Anoma Nellore, et al.
Pageof 42

Showing results (141-150 of 418) with videos related to

Sort By:
Pageof 42
The Journal of Investigative Dermatology|March 20, 2015
MITF Modulates Therapeutic Resistance through EGFR SignalingZhenyu Ji, Yiyin Erin Chen, Raj Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2011
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancerKeith T Flaherty, Patricia M Lorusso, Angela Demichele, et al.
Molecular Cancer Therapeutics|June 21, 2023
Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant MelanomaMcKenna Q Glasheen, Signe Caksa, Amelia G Young, et al.
Pigment Cell & Melanoma Research|February 1, 2017
MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathwayLisa Koetz-Ploch, Douglas Hanniford, Igor Dolgalev, et al.
Cancer Research|July 18, 2008
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpressionKeiran S M Smalley, Rooha Contractor, Thiennga K Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
Phase I trial of combretastatin a-4 phosphate with carboplatinJoshua H Bilenker, Keith T Flaherty, Mark Rosen, et al.
Cancer Discovery|December 28, 2014
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanomaBenchun Miao, Zhenyu Ji, Li Tan, et al.
Pigment Cell & Melanoma Research|November 29, 2011
Meeting report from the 2011 International Melanoma Congress, Tampa, FloridaKeiran S M Smalley, Andrew E Aplin, Keith T Flaherty, et al.
Oncoimmunology|November 20, 2013
BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytesZachary A Cooper, Dennie T Frederick, Vikram R Juneja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2008
Phase II trial of sorafenib in advanced thyroid cancerVandana Gupta-Abramson, Andrea B Troxel, Anoma Nellore, et al.
Pageof 42